Every tracked bill that moved during this week — recorded as it stood when the week closed.
Removes dyslexia from the broader 'specific learning disability' category and creates a standalone definition under federal special education law (IDEA).
Streamlines FDA approval process for biosimilars—cheaper drug versions of expensive biologics already on market.
Increases limit on copying commercial drugs from 4 to 20 times per month without FDA approval.
Automatically deems all FDA-licensed biosimilars interchangeable with brand-name originals, eliminating extra safety testing currently required.